- Telescope Innovations Corp. (TELI) has completed a four-month feasibility project funded by Pfizer (PFE) to explore accelerating pharmaceutical process development through automation
- The company created a proof-of-concept robotic to help accelerate the translation of newly identified chemistry, processes, and materials from initial discovery to scaled-up commercial deployment
- Telescope is a chemical technology company developing scalable manufacturing processes and tools for the pharmaceutical and chemical industry
- Telescope Innovations Corp. (TELI) is trading steady at $0.35 per share as of 10:10 am ET
Telescope Innovations (TELI) has completed a four-month feasibility project to explore accelerating pharmaceutical process development through automation.
The project was funded by Pfizer (PFE).
The company created a proof-of-concept robotic workflow leveraging its proprietary in-situ analytical technology and automation tools and examined how the proof-of-concept platform could evolve over the next decade.
The platform is designed to help accelerate the translation of newly identified chemistry, processes, and materials from initial discovery to scaled-up commercial deployment.
Telescope CEO Jason Hein stated that high-quality data is the key to unlock the potential of these tools to enable companies to achieve faster product discovery and development.
“Deploying our automation and analytical platforms to support the pharmaceutical industry is a key strategic aim for Telescope.”
Telescope is a chemical technology company developing scalable manufacturing processes and tools for the pharmaceutical and chemical industry.
Telescope Innovations Corp. (TELI) is trading steady at $0.35 per share as of 10:10 am ET.